Ces radiol. 2010, 64(1):44-51
18F-FDG-PET/CT of the musculoskeletal tumorsOriginal article
- Klinika zobrazovacích metod LF UK a FN v Plzni
Aim: To assess the feasibility of the 18F-FDG-PET/CT in the staging, restaging and therapy response evaluation of the tumors of the bones and soft tissues.
Method: The retrospective analyses of the cohort of 81 examinations in the 63 patients (32 males, 31 females, mean age 51.14 years, ranging 15-78 years) were performed. All procedures were performed using hybrid PET/CT with sixteen-detector-row CT subsystem after intravenous application of 18F-FDG in the dose of 5 MBq per kilogram of body weight. CT examination was performed as full diagnostic CT with sub-millimeter isotropic resolution after intravenous application of 100 ml of iodine contrast material, except cases of serious adverse reactions in patient history.
Results: The most frequent procedure was restaging in 44 cases, followed by primary staging in 21 cases, only in 16 cases the examination was performed due to the differential diagnostic reasons. According to the primary staging, the generalization of the tumor was present 62% examinations of primary staging; no residual disease activity was found in 19 cases (43%) of restaging. In differential diagnosis of dignity, the specificity of 78.9% was reached, the sensitivity of 100% respectively.
Conclusion: The 18F-FDG-PET/CT examination in tumor soft bones and soft tissue is valuable imaging tool in therapeutic decision making algorithm.
Keywords: 18F-FDG-PET, CT, soft tissue tumors, bone tumors
Accepted: January 10, 2010; Published: March 1, 2010 Show citation
References
- Murphey MD. World Health Organization classification of bone and soft tissue tumors: modifications and implications for radiologists. Semin Musculoskelet Radiol 2007; 11(3): 201-214.
Go to original source... 
Go to PubMed... - Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006; 48(1): 3-12. Go to original source... Go to PubMed...
- Kole AC, Nieweg OE, Hoekstra HJ, van Horn JR, Koops HS, Vaalburg W. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39(5): 810-815.
- Iagaru A, Masamed R, Chawla SP, Menendez LR, Fedenko A. Conti PS. F-18 FDG PET and PET. CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. Clin Nucl Med 2008; 33(1): 8-13. Go to original source... Go to PubMed...
- Franzius C, Schulte M, Hillmann A, Winkelmann W, Jürgens H, Bockisch A, Schober O. Clinical value of positron emission tomography (PET) in the diagnosis of bone and soft tissue tumors. 3rd Interdisciplinary Consensus Conference "PET in Oncology": results of the Bone and Soft Tissue Study Group Chirurg 2001; 72(9): 1071-1077. Go to original source... Go to PubMed...
- Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumor-like lesions of bone: evaluation by FDG PET. J Nucl Med 2000; 41(10): 1695-1701.
- Brenner W, Eary JF, Hwang W, Vernon C, Conrad EU. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging 2006; 33(11): 1290-1295. Go to original source... Go to PubMed...
- Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechtersheimer G, Lehnert T. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42(5): 713-720.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.